摘要
为探讨培哚普利（ｐｅｒｉｎｄｏｐｒｉｌ）对重度心力衰竭（ＣＨＦ）的疗效与血浆内皮素（ＥＴ）水平的影响，２０例经传统治疗无效的心衰患者口服 ｐｅｒｉｎｄｏｐｒｉｌ２周，观察治疗前后临床症状、血流动力学与 ＥＴ变化。结果发现，临床总有效率为 ９５％，肺动脉压（ＰＡＰ）、肺毛细血管嵌楔压（ＰＣＷＰ）比治疗前明显下降（４．９３ ± ０．５３对４．００ ± ０．５３ｋＰａ，Ｐ＜０．０１；３．４７ ± ０．５３对２．５３±０．４０ｋＰａ，Ｐ＜０．０１），体循环阻力指数（ＳＶＲＩ）下降（２０４．８ ± ２１．３对１５０．６ ±１．３ｋＰａ·Ｓ·Ｌ~－１·ｍ~－２，Ｐ＜０．０５），心指数（ＣＩ）上升（２．２±０．１对２．８±０．２２Ｌ·ｍｉｎ~－１·ｍ~－２，Ｐ＜０．０５），血浆内皮素水平明显降低（１８４．５６±４．４０对１１８±２．２４ｎｇ／Ｌ，Ｐ＜０．０１），提示ｐｅｒｉｎｄｏｐｒｉｌ可降低血浆ＥＴ水平并通过多种机制对心衰产生有益的作用。
The purpose of the present study was to explore the effects of perindopril on clinical symptoms, hemodynamics and serum level of endothelin of congestive heart failure. Twenty patients whose symptoms remained unchanged with conventional therapy were treated with perindopril for 2 weeks. The changes in clinical symptoms, hemodynamics and serum level of ET were observed. In the end of trentment, total clinical effective rate was up to 95%. The pulmonary pressure (PAP) and pulmonary capillary wedge pressure(PCWP) decreased significantly as compared with those before the treatment (4. 83 ± 0. 53 vs 4. 00 ± 0. 53kPa, P < 0. 01; 3. 47 ± 0. 53 vs 2. 53 ± 0. 40kPa, P < 0. 01 ), systemic vascular resistance index (SVRI ) increased (204. 8 ± 21. 3 vs 150. 6 ± 1. 3kPa· s· L ^-1 m^-2, P < 0. 05), ET levels decreased obviously (184. 56 ± 4. 40 vs 118. 13 ± 2. 24ng/L, P < 0. 01 ). The results showed that perindopril could decrease ET level and play a beneficial role in the treatment of congestive heart failure in combination with multiple medianisms.
出处
《标记免疫分析与临床》
CAS
2000年第3期134-136,共3页
Labeled Immunoassays and Clinical Medicine
